XML 68 R54.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements Nonrecurring Measurements (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 17, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Impairment of equity-method investments (Note 2) $ 74 $ 0  
Fair Value, Measurements, Nonrecurring [Member] | Level 3 [Member] | Investments [Member] | Northeast G And P [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Investments, Fair Value Disclosure [1]     $ 1,209
Fair Value, Measurements, Nonrecurring [Member] | Level 3 [Member] | Property Plant And Equipment, net [Member] | West [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Fair Value of Property, Plant, and Equipment [2] 0    
Fair Value, Measurements, Nonrecurring [Member] | Level 3 [Member] | Impairment Of Certain Assets [Member] | West [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Tangible Asset Impairment Charges [2] 12    
Fair Value, Measurements, Nonrecurring [Member] | Level 3 [Member] | Impairment Of Equity-Method Investments [Member] | Northeast G And P [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]      
Impairment of equity-method investments (Note 2) [1] $ 74    
[1] Relates to Northeast G&P’s equity-method investment in UEOM. The estimated fair value was determined by a market approach based on the transaction price for the purchase of the remaining interest in UEOM as finalized just prior to the signing and closing of the acquisition in March 2019 (see Note 2 – Acquisitions). This impairment is reported in Impairment of equity-method investments in the Consolidated Statement of Income.
[2] Reflects impairment of assets that are no longer in use for which the fair value was determined to be lower than the carrying value. This impairment is reported in Other (income) expense – net within Costs and expenses in the Consolidated Statement of Income.